{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:10:36Z","timestamp":1779185436064,"version":"3.51.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s44446-025-00024-4","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:25:05Z","timestamp":1752139505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Mechanistic Physiologically Based Pharmacokinetic (PBPK) modeling approach for fexofenadine: predictive pharmacokinetic insights in humans"],"prefix":"10.1007","volume":"33","author":[{"given":"Maryam","family":"Batool","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammara","family":"Zamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Alqhtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8583","authenticated-orcid":false,"given":"Muhammad Fawad","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"24_CR1","first-page":"1699","volume":"11","author":"K Abilash","year":"2022","unstructured":"Abilash K, Dinesh G, Janartanan S et al (2022) FORMULATION AND EVALUATION OF MOUTH DISSOLVING FILMS OF FEXOFENADINE HYDROCLORIDE BY SOLVENT CASTING METHOD. World J. Pharm. Res 11:1699\u20131721","journal-title":"World J. Pharm. Res"},{"issue":"4","key":"24_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17425255.2018.1459565","volume":"14","author":"Y Akamine","year":"2018","unstructured":"Akamine Y, Miura M (2018) An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 14(4):429\u2013434","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"24_CR3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/ph16121693","volume":"16","author":"F Alqahtani","year":"2023","unstructured":"Alqahtani F, Alruwaili AH, Alasmari MS et al (2023) A physiologically based pharmacokinetic model to predict systemic ondansetron concentration in liver cirrhosis patients. Pharmaceuticals 16(12):1693","journal-title":"Pharmaceuticals"},{"issue":"1","key":"24_CR4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/clpt.2012.64","volume":"92","author":"J Barrett","year":"2012","unstructured":"Barrett J, Della Casa Alberighi O, L\u00e4er S et al (2012) Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92(1):40\u201349","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"24_CR5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/pharmaceutics16121619","volume":"16","author":"M Batool","year":"2024","unstructured":"Batool M, Zamir A, Alqahtani F et al (2024) Clinical pharmacokinetics of fexofenadine: A systematic review. Pharmaceutics 16(12):1619","journal-title":"Pharmaceutics"},{"issue":"3","key":"24_CR6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00228-016-2173-3","volume":"73","author":"SK Bedada","year":"2017","unstructured":"Bedada SK, Boga PK (2017) The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. Eur J Clin Pharmacol 73(3):343\u2013349","journal-title":"Eur J Clin Pharmacol"},{"key":"24_CR7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4172\/jbb.10000198","volume":"6","author":"SK Bedada","year":"2014","unstructured":"Bedada SK, Yakkanti SA, Neerati P (2014) Resveratrol enhances the bioavailability of fexofenadine in healthy human male volunteers: involvement of P-glycoprotein inhibition. J Bioequiv Availab 6:158\u2013163","journal-title":"J Bioequiv Availab"},{"issue":"3","key":"24_CR8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/00498254.2016.1180564","volume":"47","author":"SK Bedada","year":"2017","unstructured":"Bedada SK, Boga PK, Kotakonda HK (2017) The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. Xenobiotica 47(3):230\u2013235","journal-title":"Xenobiotica"},{"issue":"2","key":"24_CR9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/bdd.1767","volume":"33","author":"F Bouzom","year":"2012","unstructured":"Bouzom F, Ball K, Perdaems N et al (2012) Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos 33(2):55\u201371","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"24_CR10","first-page":"5","volume":"10","author":"CM Bowman","year":"2021","unstructured":"Bowman CM, Ma F, Mao J et al (2021) Examination of physiologically-based pharmacokinetic models of rosuvastatin. CPT: Pharmacometrics Syst Pharmacol 10(1):5\u201317","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"24_CR11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1185\/030079905X59175","volume":"21","author":"J Boyle","year":"2005","unstructured":"Boyle J, Ridout F, Meadows R et al (2005) Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers. Curr Med Res Opin 21(9):1495\u20131503","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"24_CR12","first-page":"1261","volume":"27","author":"Y-A Chen","year":"2014","unstructured":"Chen Y-A, Hsu K-Y (2014) Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers. Pak J Pharm Sci 27(5):1261\u20131264","journal-title":"Pak J Pharm Sci"},{"issue":"13","key":"24_CR13","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME (2019) Chronic kidney disease diagnosis and management: a review. JAMA 322(13):1294\u20131304","journal-title":"JAMA"},{"issue":"3","key":"24_CR14","first-page":"510","volume":"14","author":"S Chen","year":"2025","unstructured":"Chen S, Shen C, Tian Y et al (2025) Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug\u2013drug interactions. CPT: Pharmacometrics Syst Pharmacol 14(3):510\u2013522","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"24_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00003088-200847040-00001","volume":"47","author":"P Devillier","year":"2008","unstructured":"Devillier P, Roche N, Faisy C (2008) Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 47:217\u2013230","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"24_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1067\/mcp.2002.121152","volume":"71","author":"GK Dresser","year":"2002","unstructured":"Dresser GK, Bailey DG, Leake BF et al (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71(1):11\u201320","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"24_CR17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/pharmaceutics13030310","volume":"13","author":"BB Eedara","year":"2021","unstructured":"Eedara BB, Nyavanandi D, Narala S et al (2021) Improved dissolution rate and intestinal absorption of fexofenadine hydrochloride by the preparation of solid dispersions: In vitro and in situ evaluation. Pharmaceutics 13(3):310","journal-title":"Pharmaceutics"},{"key":"24_CR18","volume-title":"FEXOFENADINE AND ORGANIC ANION TRANSPORTING POLYPEPTIDES (OATPs): TRANSPORT AND DRUG-DRUG INTERACTIONS","author":"CA Flynn","year":"2011","unstructured":"Flynn CA (2011) FEXOFENADINE AND ORGANIC ANION TRANSPORTING POLYPEPTIDES (OATPs): TRANSPORT AND DRUG-DRUG INTERACTIONS. University of Kansas"},{"issue":"S1","key":"24_CR19","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jcph.1741","volume":"60","author":"Y Franchetti","year":"2020","unstructured":"Franchetti Y, Nolin TD (2020) Dose optimization in kidney disease: opportunities for PBPK modeling and simulation. J Clin Pharmacol 60(S1):S36\u2013S51","journal-title":"J Clin Pharmacol"},{"key":"24_CR20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11095-021-03109-6","volume":"38","author":"N Hanke","year":"2021","unstructured":"Hanke N, G\u00f3mez-Mantilla JD, Ishiguro N et al (2021) Physiologically based pharmacokinetic modeling of rosuvastatin to predict transporter-mediated drug-drug interactions. Pharm Res 38:1645\u20131661","journal-title":"Pharm Res"},{"issue":"7","key":"24_CR21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/tde-2020-0042","volume":"11","author":"SA Helmy","year":"2020","unstructured":"Helmy SA, El-Bedaiwy HM, El-Masry SM (2020) Applying biopharmaceutical classification system criteria to predict the potential effect of cremophor(\u00ae) RH 40 on fexofenadine bioavailability at higher doses. Ther Deliv 11(7):447\u2013464","journal-title":"Ther Deliv"},{"issue":"1","key":"24_CR22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yrtph.2013.09.008","volume":"69","author":"EAC Hubal","year":"2014","unstructured":"Hubal EAC, de Wet T, Du Toit L et al (2014) Identifying important life stages for monitoring and assessing risks from exposures to environmental contaminants: results of a World Health Organization review. Regul Toxicol Pharmacol 69(1):113\u2013124","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"24_CR23","first-page":"1","volume":"1","author":"W Huisinga","year":"2012","unstructured":"Huisinga W, Solms A, Fronton L et al (2012) Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT: Pharmacometrics Syst Pharmacol 1(9):1\u201310","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"24_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","volume":"43","author":"S Izumi","year":"2015","unstructured":"Izumi S, Nozaki Y, Maeda K et al (2015) Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43(2):235\u2013247","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"24_CR25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40005-023-00615-0","volume":"53","author":"J-H Jang","year":"2023","unstructured":"Jang J-H, Jeong S-H, Lee Y-B (2023) Establishment of a fexofenadine population pharmacokinetic (PK)\u2013pharmacodynamic (PD) model and exploration of dosing regimens through simulation. J Pharm Investig 53(3):427\u2013441","journal-title":"J Pharm Investig"},{"issue":"3","key":"24_CR26","first-page":"373","volume":"11","author":"TN Johnson","year":"2022","unstructured":"Johnson TN, Small BG, Rowland Yeo K (2022) Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT: Pharmacometr Syst Pharmacol 11(3):373\u2013383","journal-title":"CPT: Pharmacometr Syst Pharmacol"},{"issue":"12","key":"24_CR27","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1124\/dmd.113.053991","volume":"41","author":"ED Kharasch","year":"2013","unstructured":"Kharasch ED, Stubbert K (2013) Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir. Drug Metab Dispos 41(12):2166\u20132174","journal-title":"Drug Metab Dispos"},{"key":"24_CR28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-010-0797-2","volume":"66","author":"K-A Kim","year":"2010","unstructured":"Kim K-A, Park J-Y (2010) Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol 66:721\u2013725","journal-title":"Eur J Clin Pharmacol"},{"key":"24_CR29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","volume":"57","author":"ES Kostewicz","year":"2014","unstructured":"Kostewicz ES, Aarons L, Bergstrand M et al (2014) PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 57:300\u2013321","journal-title":"Eur J Pharm Sci"},{"key":"24_CR30","doi-asserted-by":"crossref","first-page":"baae063","DOI":"10.1093\/database\/baae063","volume":"2024","author":"L Krumpholz","year":"2024","unstructured":"Krumpholz L, Klimczyk A, Bieniek W et al (2024) Data set of fraction unbound values in the in vitro incubations for metabolic studies for better prediction of human clearance. Database. 2024:baae063","journal-title":"Database."},{"key":"24_CR31","doi-asserted-by":"crossref","unstructured":"Kumar L, Alam MS, Meena CL, et al. Fexofenadine hydrochloride.Profiles of drug substances, excipients and related methodology. Vol. 34: Elsevier; 2009. p. 153\u2013192.","DOI":"10.1016\/S1871-5125(09)34004-2"},{"issue":"2","key":"24_CR32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2010.03.009","volume":"40","author":"G Lappin","year":"2010","unstructured":"Lappin G, Shishikura Y, Jochemsen R et al (2010) Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40(2):125\u2013131","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"24_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1208\/s12249-018-1253-3","volume":"20","author":"M Lavan","year":"2019","unstructured":"Lavan M, Byrn SR, Knipp G (2019) Pediatric formulations: knowledge gaps limiting the expedited preclinical to clinical translation in children. AAPS PharmSciTech 20(2):73","journal-title":"AAPS PharmSciTech"},{"issue":"10\u201311","key":"24_CR34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00498250701704819","volume":"37","author":"H Lennern\u00e4s","year":"2007","unstructured":"Lennern\u00e4s H (2007) Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37(10\u201311):1015\u20131051","journal-title":"Xenobiotica"},{"issue":"4","key":"24_CR35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/cts.12400","volume":"9","author":"J Luo","year":"2016","unstructured":"Luo J, Imai H, Ohyama T et al (2016) The pharmacokinetic exposure to fexofenadine is volume-dependently reduced in healthy subjects following oral administration with apple juice. Clin Transl Sci 9(4):201\u2013206","journal-title":"Clin Transl Sci"},{"issue":"1","key":"24_CR36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5507\/bp.2007.011","volume":"151","author":"L Mendoza","year":"2007","unstructured":"Mendoza L, Begany P, Dyrhonova M et al (2007) Bioequivalence of two fexofenadine formulations in healthy human volunteers after single oral administration. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151(1):65\u201367","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"5","key":"24_CR37","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1021\/mp200026v","volume":"8","author":"X Ming","year":"2011","unstructured":"Ming X, Knight BM, Thakker DR (2011) Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm 8(5):1677\u20131686","journal-title":"Mol Pharm"},{"issue":"4","key":"24_CR38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1472-8206.2004.00254.x","volume":"18","author":"M Molimard","year":"2004","unstructured":"Molimard M, Diquet B, Benedetti MS (2004) Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 18(4):399\u2013411","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"24_CR39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/bmc.3114","volume":"28","author":"R Muppavarapu","year":"2014","unstructured":"Muppavarapu R, Guttikar S, Rajappan M et al (2014) Sensitive LC-MS\/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. Biomed Chromatogr 28(8):1048\u20131056","journal-title":"Biomed Chromatogr"},{"issue":"20","key":"24_CR40","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/rcm.2701","volume":"20","author":"RV Nirogi","year":"2006","unstructured":"Nirogi RV, Kandikere VN, Shukla M et al (2006) Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography\/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. Rapid Commun Mass Spectrom 20(20):3030\u20133038","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"10","key":"24_CR41","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","volume":"20","author":"TD Nolin","year":"2009","unstructured":"Nolin TD, Frye RF, Le P et al (2009) ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 20(10):2269\u20132276","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"24_CR42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/ph17070924","volume":"17","author":"M Pasha","year":"2024","unstructured":"Pasha M, Zamir A, Rasool MF et al (2024) A comprehensive physiologically based pharmacokinetic model for predicting vildagliptin pharmacokinetics: insights into dosing in renal impairment. Pharmaceuticals 17(7):924","journal-title":"Pharmaceuticals"},{"key":"24_CR43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40495-020-00212-x","volume":"6","author":"C Perry","year":"2020","unstructured":"Perry C, Davis G, Conner TM et al (2020) Utilization of physiologically based pharmacokinetic modeling in clinical pharmacology and therapeutics: an overview. Curr Pharmacol Rep 6:71\u201384","journal-title":"Curr Pharmacol Rep"},{"key":"24_CR44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11095-021-03035-7","volume":"38","author":"L Pinto","year":"2021","unstructured":"Pinto L, Bapat P, de Lima MF et al (2021) Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. Pharm Res 38:647\u2013655","journal-title":"Pharm Res"},{"issue":"3","key":"24_CR45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/10837450902891527","volume":"41","author":"I Poggesi","year":"2009","unstructured":"Poggesi I, Benedetti MS, Whomsley R et al (2009) Pharmacokinetics in special populations. Drug Metab Rev 41(3):422\u2013454","journal-title":"Drug Metab Rev"},{"issue":"6","key":"24_CR46","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/mp8002495","volume":"6","author":"A Poirier","year":"2009","unstructured":"Poirier A, Funk C, Scherrmann J-M et al (2009) Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 6(6):1716\u20131733","journal-title":"Mol Pharm"},{"issue":"1","key":"24_CR47","doi-asserted-by":"crossref","first-page":"473213","DOI":"10.1155\/2014\/473213","volume":"2014","author":"F Qiu","year":"2014","unstructured":"Qiu F, Zeng J, Liu S et al (2014) Effects of danshen ethanol extract on the pharmacokinetics of fexofenadine in healthy volunteers. Evid-Based Complement Alternat Med 2014(1):473213","journal-title":"Evid-Based Complement Alternat Med"},{"key":"24_CR48","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40262-015-0253-7","volume":"54","author":"MF Rasool","year":"2015","unstructured":"Rasool MF, Khalil F, L\u00e4er S (2015) A physiologically based pharmacokinetic drug\u2013disease model to predict carvedilol exposure in adult and Paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet 54:943\u2013962","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"24_CR49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/(SICI)1099-081X(199810)19:7<455::AID-BDD130>3.0.CO;2-W","volume":"19","author":"DK Robbins","year":"1998","unstructured":"Robbins DK, Castles MA, Pack DJ et al (1998) Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 19(7):455\u2013463","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"24_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/ecp.10.143","volume":"4","author":"K Rowland Yeo","year":"2011","unstructured":"Rowland Yeo K, Aarabi M, Jamei M et al (2011) Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol 4(2):261\u2013274","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"24_CR51","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I et al (2015) Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos 43(11):1823\u20131837","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"24_CR52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/dmd.105.004622","volume":"33","author":"M Shimizu","year":"2005","unstructured":"Shimizu M, Fuse K, Okudaira K et al (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33(10):1477\u20131481","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"24_CR53","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2125.2006.02613.x","volume":"61","author":"M Shimizu","year":"2006","unstructured":"Shimizu M, Uno T, Sugawara K et al (2006) Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 61(5):538\u2013544","journal-title":"Br J Clin Pharmacol"},{"key":"24_CR54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s11095-014-1305-7","volume":"31","author":"Y Shirasaka","year":"2014","unstructured":"Shirasaka Y, Mori T, Murata Y et al (2014) Substrate-and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. Pharm Res 31:2035\u20132043","journal-title":"Pharm Res"},{"issue":"1","key":"24_CR55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","volume":"34","author":"Y Shitara","year":"2013","unstructured":"Shitara Y, Maeda K, Ikejiri K et al (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34(1):45\u201378","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"24_CR56","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0091-6749(96)80192-8","volume":"98","author":"FER Simons","year":"1996","unstructured":"Simons FER, Bergman JN, Watson WTA, Simons KJ (1996) The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 98(6):1062\u20131064","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"24_CR57","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/mp500834v","volume":"12","author":"E Sj\u00f6gren","year":"2015","unstructured":"Sj\u00f6gren E, Dahlgren D, Roos C et al (2015) Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data. Mol Pharm 12(6):2026\u20132039","journal-title":"Mol Pharm"},{"issue":"6","key":"24_CR58","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1021\/acs.molpharmaceut.5b00861","volume":"13","author":"E Sj\u00f6gren","year":"2016","unstructured":"Sj\u00f6gren E, Thorn H, Tannergren C (2016) In silico modeling of gastrointestinal drug absorption: predictive performance of three physiologically based absorption models. Mol Pharm 13(6):1763\u20131778","journal-title":"Mol Pharm"},{"key":"24_CR59","first-page":"64","volume":"87","author":"S Suvanto","year":"2014","unstructured":"Suvanto S (2014) P-Glycoprotein characteristics and investigation of P-glycoprotein mediated drug-drug interactions with in vitro methods. Am J Trop Med Hyg 87:64\u201369","journal-title":"Am J Trop Med Hyg"},{"key":"24_CR60","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1007\/s11095-009-9909-z","volume":"26","author":"B Swift","year":"2009","unstructured":"Swift B, Tian X, Brouwer KL (2009) Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm Res 26:1942\u20131951","journal-title":"Pharm Res"},{"issue":"11","key":"24_CR61","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1124\/dmd.116.070011","volume":"44","author":"J Takano","year":"2016","unstructured":"Takano J, Maeda K, Bolger MB et al (2016) The prediction of the relative importance of CYP3A\/P-glycoprotein to the nonlinear intestinal absorption of drugs by advanced compartmental absorption and transit model. Drug Metab Dispos 44(11):1808\u20131818","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"24_CR62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0009-9236(03)00238-8","volume":"74","author":"C Tannergren","year":"2003","unstructured":"Tannergren C, Petri N, Knutson L et al (2003) Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin Pharmacol Ther 74(5):423\u2013436","journal-title":"Clin Pharmacol Ther"},{"key":"24_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-018-0187-8","volume":"20","author":"IE Templeton","year":"2018","unstructured":"Templeton IE, Jones NS, Musib L (2018) Pediatric dose selection and utility of PBPK in determining dose. AAPS J 20:1\u20139","journal-title":"AAPS J"},{"issue":"5","key":"24_CR64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1005-9040(07)60112-3","volume":"23","author":"GS Teng","year":"2007","unstructured":"Teng GS, Teng LS, Yi WU et al (2007) Rapid and Sensitive LC-MS\/MS Method for Quantification of Fexofenadine in Human Plasma\u2014\u2013Application to a Bioequivalence Study in Chinese Volunteers. Chem Res Chin Univ 23(5):514\u2013517","journal-title":"Chem Res Chin Univ"},{"issue":"4","key":"24_CR65","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.ajkd.2014.09.015","volume":"65","author":"BK Thomson","year":"2015","unstructured":"Thomson BK, Nolin TD, Velenosi TJ et al (2015) Effect of CKD and Dialysis Modality on Exposure to Drugs Cleared by Nonrenal Mechanisms. Am J Kidney Dis 65(4):574\u2013582","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"24_CR66","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jpba.2004.02.036","volume":"35","author":"T Uno","year":"2004","unstructured":"Uno T, Yasui-Furukori N, Takahata T et al (2004) Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal 35(4):937\u2013942","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"24_CR67","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1124\/dmd.106.011023","volume":"34","author":"T Uno","year":"2006","unstructured":"Uno T, Shimizu M, Sugawara K et al (2006) Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 34(11):1875\u20131879","journal-title":"Drug Metab Dispos"},{"issue":"3\u20134","key":"24_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J (2002) Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP 32(3\u20134):1\u2013277","journal-title":"Ann ICRP"},{"issue":"7","key":"24_CR69","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0091270006288733","volume":"46","author":"RP van Heeswijk","year":"2006","unstructured":"van Heeswijk RP, Bourbeau M, Campbell P et al (2006) Time-dependent interaction between lopinavir\/ritonavir and fexofenadine. J Clin Pharmacol 46(7):758\u2013767","journal-title":"J Clin Pharmacol"},{"key":"24_CR70","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A et al (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34:401\u2013431","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1\u20132","key":"24_CR71","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jchromb.2007.08.011","volume":"858","author":"N Yamane","year":"2007","unstructured":"Yamane N, Tozuka Z, Sugiyama Y et al (2007) Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography\/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 858(1\u20132):118\u2013128","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"24_CR72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2710.2009.01159.x","volume":"35","author":"A Yamazaki","year":"2010","unstructured":"Yamazaki A, Kumagai Y, Yamane N et al (2010) Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC\/MS\/MS. J Clin Pharm Ther 35(2):169\u2013175","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"24_CR73","doi-asserted-by":"crossref","first-page":"101675","DOI":"10.1016\/j.jsps.2023.06.008","volume":"31","author":"MT Zahid","year":"2023","unstructured":"Zahid MT, Zamir A, Majeed A et al (2023) A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations. Saudi Pharm J 31(8):101675","journal-title":"Saudi Pharm J"},{"issue":"32","key":"24_CR74","doi-asserted-by":"crossref","first-page":"29302","DOI":"10.1021\/acsomega.3c02673","volume":"8","author":"A Zamir","year":"2023","unstructured":"Zamir A, Rasool MF, Imran I et al (2023) Physiologically based pharmacokinetic model to predict metoprolol disposition in healthy and disease populations. ACS Omega 8(32):29302\u201329313","journal-title":"ACS Omega"},{"key":"24_CR75","doi-asserted-by":"crossref","first-page":"630904","DOI":"10.3389\/fphar.2021.630904","volume":"12","author":"SE Zapke","year":"2021","unstructured":"Zapke SE, Willmann S, Grebe S-O et al (2021) Comparing predictions of a PBPK model for cyclosporine with drug levels from therapeutic drug monitoring. Front Pharmacol 12:630904","journal-title":"Front Pharmacol"},{"issue":"3","key":"24_CR76","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jep.2013.01.037","volume":"146","author":"Q Zhou","year":"2013","unstructured":"Zhou Q, Ye Z, Ruan Z et al (2013) Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. J Ethnopharmacol 146(3):744\u2013749","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"24_CR77","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","volume":"6","author":"X Zhuang","year":"2016","unstructured":"Zhuang X, Lu C (2016) PBPK modeling and simulation in drug research and development. Acta Pharmaceutica Sinica b 6(5):430\u2013440","journal-title":"Acta Pharmaceutica Sinica b"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00024-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-025-00024-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00024-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:49:18Z","timestamp":1757486958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-025-00024-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s44446-025-00024-4","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"24"}}